132 related articles for article (PubMed ID: 20947485)
1. Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab.
Maximiano Alonso C; Sánchez Ruiz AC; Cantos Sánchez de Ibargüen B; Méndez García M; Ronco IS; Provencio Pulla M
Clin Transl Oncol; 2010 Oct; 12(10):701-3. PubMed ID: 20947485
[TBL] [Abstract][Full Text] [Related]
2. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma.
Ohguro N; Hashida N; Tano Y
Arch Ophthalmol; 2008 Jul; 126(7):1002-3. PubMed ID: 18625954
[No Abstract] [Full Text] [Related]
3. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.
Wilson WH; Bromberg JE; Stetler-Stevenson M; Steinberg SM; Martin-Martin L; Muñiz C; Sancho JM; Caballero MD; Davidis MA; Brooimans RA; Sanchez-Gonzalez B; Salar A; González-Barca E; Ribera JM; Shovlin M; Filie A; Dunleavy K; Mehrling T; Spina M; Orfao A
Haematologica; 2014 Jul; 99(7):1228-35. PubMed ID: 24727817
[TBL] [Abstract][Full Text] [Related]
4. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
6. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy with autologous stem cell transplantation following systemic chemotherapy, prophylactic intrathecal methotrexate, and radiotherapy prevents relapse and improves the outcome of advanced stage primary testicular lymphoma even with cardiac involvement.
Lee S; Yamauchi T; Kinoshita K; Imamura S; Kamiya K
J Clin Exp Hematop; 2017 Oct; 57(2):64-68. PubMed ID: 28883219
[TBL] [Abstract][Full Text] [Related]
8. Successful long-term control of lymphomatous meningitis with intraventricular rituximab.
Birnbaum T; Baumgarten Lv; Dudel C; Straube A
J Clin Neurosci; 2014 Feb; 21(2):356-8. PubMed ID: 24054402
[TBL] [Abstract][Full Text] [Related]
9. [Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma].
Kikuchi A; Kawada H; Iwaki Y; Machida S; Tsuchiya T; Fukuda R; Hotta T
Rinsho Ketsueki; 2004 Dec; 45(12):1255-7. PubMed ID: 15678918
[TBL] [Abstract][Full Text] [Related]
10. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature.
Pels H; Schulz H; Schlegel U; Engert A
Onkologie; 2003 Aug; 26(4):351-4. PubMed ID: 12972702
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections.
Savino G; Battendieri R; Gari M; Caputo CG; Laurenti L; Blasi MA
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1251-5. PubMed ID: 23625184
[TBL] [Abstract][Full Text] [Related]
12. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab.
Miyazaki K; Yamaguchi M; Suzuki R; Kobayashi Y; Maeshima AM; Niitsu N; Ennishi D; Tamaru JI; Ishizawa K; Kashimura M; Kagami Y; Sunami K; Yamane H; Nishikori M; Kosugi H; Yujiri T; Hyo R; Katayama N; Kinoshita T; Nakamura S
Ann Oncol; 2011 Jul; 22(7):1601-1607. PubMed ID: 21199885
[TBL] [Abstract][Full Text] [Related]
13. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice.
Mineo JF; Scheffer A; Karkoutly C; Nouvel L; Kerdraon O; Trauet J; Bordron A; Dessaint JP; Labalette M; Berthou C; Labalette P
Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4738-45. PubMed ID: 18552383
[TBL] [Abstract][Full Text] [Related]
14. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system.
van de Glind G; de Graaf S; Klein C; Cornelissen M; Maecker B; Loeffen J
Pediatr Blood Cancer; 2008 Apr; 50(4):886-8. PubMed ID: 17668865
[TBL] [Abstract][Full Text] [Related]
16. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
[TBL] [Abstract][Full Text] [Related]
17. Prevention of CNS relapse in diffuse large B-cell lymphoma.
Kridel R; Dietrich PY
Lancet Oncol; 2011 Dec; 12(13):1258-66. PubMed ID: 21933751
[TBL] [Abstract][Full Text] [Related]
18. Intraventricular Rituximab in Pediatric CD20-positive Refractory Primary Central Nervous System Lymphoma.
Wada-Shimosato Y; Ikeda J; Tsujimoto SI; Sasaki K; Yanagimachi M; Kajiwara R; Shiba N; Murata H; Kawahara N; Yamanaka S; Tanoshima R; Ito S
J Pediatr Hematol Oncol; 2019 Oct; 41(7):571-573. PubMed ID: 30124546
[TBL] [Abstract][Full Text] [Related]
19. Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.
Kersten MJ; Kraan W; Doorduijn J; Bromberg J; Lam K; Kluin PM; van der Holt BJ; Spaargaren M; Pals ST
Blood Cancer J; 2014 Dec; 4(12):e266. PubMed ID: 25501023
[No Abstract] [Full Text] [Related]
20. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
